Article
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Journal of gastroenterology - 1 Sept 2018
Kakuta Yoichi, Kawai Yosuke, Okamoto Daisuke, Takagawa Tetsuya, Ikeya Kentaro, Sakuraba Hirotake, Nishida Atsushi, Nakagawa Shoko, Miura Miki, Toyonaga Takahiko, Onodera Kei, Shinozaki Masaru, Ishiguro Yoh, Mizuno Shinta, Takahara Masahiro, Yanai Shunichi, Hokari Ryota, Nakagawa Tomoo, Araki Hiroshi, Motoya Satoshi, Naito Takeo, Moroi Rintaro, Shiga Hisashi, Endo Katsuya, Kobayashi Taku, Naganuma Makoto, Hiraoka Sakiko, Matsumoto Takayuki, Nakamura Shiro, Nakase Hiroshi, Hisamatsu Tadakazu, Sasaki Makoto, Hanai Hiroyuki, Andoh Akira, Nagasaki Masao, Kinouchi Yoshitaka, Shimosegawa Tooru, Masamune Atsushi, Suzuki Yasuo
Abstract excerpt
BACKGROUND: Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs. To clarify the best pharmacogenetic test to be used clinically, we performed association studies of NUDT15 variants and haplotypes with AEs, genome-wide association study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.